Clinical (A) and CMR (B) baseline characteristics.
| (A) Clinical | All patients (n=91) |
| Age (years) | 49.9±16.8 |
| Male (%) | 69 (76) |
| BSA (m2) | 1.92±0.2 |
| Family history of HCM, n(%) | 32 (35) |
| Comorbidities | |
| Diabetes, n(%) | 5 (5) |
| Hypertension, n(%) | 27 (30) |
| Hypercholesterolaemia, n(%) | 22 (24) |
| Renal insufficiency (GFR <60 mL/min), n(%) | 9 (10) |
| CAD, n(%) | 0 (0) |
| Class NYHA III-IV n(%) | 12 (13) |
| (B) CMR | All patients | HOCM | HNCM | P value |
| LVEF (%) | 65.3±8.6 | 67.0±6.5 | 63.6±10.0 | 0.116 |
| IVS (mm) | 19.6±4.0 | 20.9±3.6 | 18.3±3.9 | <0.001 |
| LVMi (g/m2) | 85.0±29.6 | 90.8±29.4 | 79.3±29.4 | 0.032 |
| LVEDVi (mL) | 74.8±16.3 | 75.1±14.8 | 74.4±17.9 | 0.520 |
| T2* (ms) | 26.5±4.6 | 25.5±4.0 | 27.4±4.9 | 0.055 |
BSA, body surface area; CAD, coronary artery diseases; CMR, cardiovascular magnetic resonance; GFR, glomerular filtration rate; HCM, hypertrophic cardiomyopathy; HNCM, hypertrophic non-obstructive cardiomyopathy; HOCM, hypertrophic obstructive cardiomyopathy; IVS, interventricular septum; LVEDVi, left ventricular indexed end-diastolic volume; LVEF, left ventricular ejection fraction; LVMi, left ventricular indexed mass; NYHA, New York Heart Association.